EcoDrugPlus

Egl Nine Homolog 3-Like

Ensembl ID : ENSNBRG00000022731
Gene Symbol: LOC102783276
3 Cross references
198 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSNBRG00000020049
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSNBRG00000005857
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Endothelin Receptor Type Ab

Ensembl ID : ENSNBRG00000002625
Gene Symbol: EDNRAB
2 Cross references
197 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSNBRG00000009214
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin-1 Receptor-Like

Ensembl ID : ENSNBRG00000004980
Gene Symbol: LOC102790675
3 Cross references
205 Possible Orthologues:

Endothelin-Converting Enzyme 1-Like

Ensembl ID : ENSNBRG00000010451
Gene Symbol: LOC102779120
3 Cross references
230 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSNBRG00000009443
Gene Symbol: EZH2
1 Cross references
233 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSNBRG00000007045
Gene Symbol: LOC102782543
3 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSNBRG00000013852
Gene Symbol: LOC102778768
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSNBRG00000002383
Gene Symbol: ERBB4
3 Cross references
47 Possible Orthologues:

Estrogen Receptor Beta-Like

Ensembl ID : ENSNBRG00000023185
Gene Symbol: LOC102788126
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).